Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Solving Challenging Puzzles: Heather Jacene Talks with Johannes Czernin About Leadership in Clinical Nuclear Medicine and the SNMMI.
J Nucl Med
November 2024
David Geffen School of Medicine at UCLA, Los Angeles, California.
Radiotherapy and theranostics: a Lancet Oncology Commission.
Lancet Oncol
November 2024
Department of Molecular Imaging and Therapy, Austin Health, Melbourne, VIC, Australia; Olivia Newton-John Cancer Research Institute, Melbourne, VIC, Australia; School of Cancer Medicine, La Trobe University, Melbourne, VIC, Australia; Faculty of Medicine, University of Melbourne, Melbourne, VIC, Australia. Electronic address:
Article Synopsis
- - The Lancet Oncology Commission focuses on improving global access to radiotherapy and theranostics, addressing significant disparities between high-income countries and low-income and middle-income countries (LMICs) concerning available treatment resources and trained healthcare professionals.
- - The implementation of hypofractionation techniques in radiotherapy could increase treatment access for millions of patients with prostate and breast cancer, highlighting the need for new technologies in LMICs with existing resources.
- - A global survey revealed variability in the use of radiopharmaceutical therapy, with issues related to supply chains and workforce training impacting access; initiatives like the International Atomic Energy Agency's Rays of Hope program and investment from development banks are encouraged to improve the situation.
Impact of Clinical Factors on F-Flotufolastat Detection Rates in Men With Recurrent Prostate Cancer: Exploratory Analysis of the Phase 3 SPOTLIGHT Study.
Adv Radiat Oncol
August 2024
Division of Nuclear Medicine and Molecular Imaging, Department of Radiology and Imaging Sciences, Emory University, Atlanta, Georgia.
Article Synopsis
- F-Flotufolastat is a newly approved diagnostic imaging drug targeting prostate cancer, evaluated in the SPOTLIGHT clinical trial, which aimed to understand its detection rates based on clinical factors in men suspected of prostate cancer recurrence.* -
- The study involved 389 men and found that detection rates increased significantly with higher baseline prostate-specific antigen (PSA) levels, identifying lesions in 39% of those with prior radical prostatectomy and 43% of those with prior radiation therapy.* -
- Despite varying PSA doubling times and pathologic grades, the detection rates remained consistently high across different patient categories, suggesting effectiveness of F-flotufolastat across a wide range of clinical scenarios.*
Presenilin-1 mutation position influences amyloidosis, small vessel disease, and dementia with disease stage.
Alzheimers Dement
April 2024
Washington University School of Medicine in Saint Louis, St. Louis, Missouri, USA.
Introduction: Amyloidosis, including cerebral amyloid angiopathy, and markers of small vessel disease (SVD) vary across dominantly inherited Alzheimer's disease (DIAD) presenilin-1 (PSEN1) mutation carriers. We investigated how mutation position relative to codon 200 (pre-/postcodon 200) influences these pathologic features and dementia at different stages.
Methods: Individuals from families with known PSEN1 mutations (n = 393) underwent neuroimaging and clinical assessments.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!